Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.21 - $5.81 $41,258 - $56,937
9,800 Added 46.89%
30,700 $129,000
Q1 2024

May 15, 2024

SELL
$5.78 - $7.33 $215,594 - $273,409
-37,300 Reduced 64.09%
20,900 $126,000
Q4 2023

Feb 14, 2024

BUY
$3.6 - $7.15 $145,440 - $288,860
40,400 Added 226.97%
58,200 $408,000
Q3 2023

Nov 14, 2023

SELL
$4.79 - $7.19 $56,522 - $84,842
-11,800 Reduced 39.86%
17,800 $87,000
Q2 2023

Aug 14, 2023

BUY
$5.19 - $8.07 $61,761 - $96,033
11,900 Added 67.23%
29,600 $198,000
Q1 2023

May 15, 2023

BUY
$5.04 - $8.6 $77,112 - $131,580
15,300 Added 637.5%
17,700 $91,000
Q4 2022

Feb 14, 2023

SELL
$5.8 - $8.98 $106,140 - $164,334
-18,300 Reduced 88.41%
2,400 $15,000
Q3 2022

Nov 14, 2022

BUY
$7.55 - $11.25 $156,285 - $232,875
20,700 New
20,700 $174,000

Others Institutions Holding MGTX

About MeiraGTx Holdings plc


  • Ticker MGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,010,700
  • Market Cap $176M
  • Description
  • MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...
More about MGTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.